The drug will be marketed as an obesity treatment under the name Zepbound.
The Food and Drug Administration on Wednesday approved a hotly anticipated Eli Lilly obesity treatment, cracking the lid on what is widely expected to be one of the top-selling medicines in history.
The Lilly drug, which will be marketed as an obesity treatment under the name Zepbound, is already sold as a diabetes treatment under the name Mounjaro. It will compete directly with Novo Nordisk’s obesity drug Wegovy. The FDA said Wednesday that patients without diabetes in one trial lost 18% of their body weight after taking Zepbound for 72 weeks. The agency approved Zepbound for adults with obesity, or who are overweight and have at least one weight related condition, such as high blood pressure or high cholesterol.
Lilly shares have risen 65% this year, largely due to investor enthusiasm for the drug now known as Zepbound.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for the Stock.The company desperately needs some of the obesity drug fervor that's lifted Lilly and Novo.
Consulte Mais informação »
Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for the Stock.The company desperately needs some of the obesity drug fervor that's lifted Lilly and Novo.
Consulte Mais informação »
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Consulte Mais informação »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Consulte Mais informação »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Consulte Mais informação »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Consulte Mais informação »